GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Price-to-Owner-Earnings

KYTHERA Biopharmaceuticals (FRA:KYT) Price-to-Owner-Earnings : (As of May. 08, 2024)


View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-08), KYTHERA Biopharmaceuticals's share price is €66.74. KYTHERA Biopharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


FRA:KYT's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.075
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-08), KYTHERA Biopharmaceuticals's share price is €66.74. KYTHERA Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 was €-4.06. Therefore, KYTHERA Biopharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-08), KYTHERA Biopharmaceuticals's share price is €66.74. KYTHERA Biopharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was €-4.07. Therefore, KYTHERA Biopharmaceuticals's PE Ratio without NRI for today is At Loss.


KYTHERA Biopharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Price-to-Owner-Earnings Chart

KYTHERA Biopharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14
Price-to-Owner-Earnings
- - - - -

KYTHERA Biopharmaceuticals Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings falls into.



KYTHERA Biopharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=66.74/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KYTHERA Biopharmaceuticals  (FRA:KYT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


KYTHERA Biopharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Traded in Other Exchanges
N/A
Address
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines